Follicular Lymphoma

Follicular Lymphoma

Epigenetics of Indolent Lymphoma and How It Drives Novel Therapeutic Approaches—Focus on EZH2-Targeted Drugs

Epigenetic modifier gene mutations are common in patients with FL.

Current Oncology Reports
The Value of Complete Remission According to Positron Emission Tomography Prior to Autologous Stem Cell Transplantation in Lymphoma: A Population-Based Study Showing Improved Outcome

CAR T-cell and bispecific antibody therapies will likely necessitate a reconsideration of the role of ASCT in lymphoma. Patients who are likely to profit from ASCT need to be better identified.

BMC Cancer
EHA Endorsement of ESMO Clinical Practice Guidelines for Newly Diagnosed and Relapsed Follicular Lymphoma

The ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up for Follicular Lymphoma released in the late 2020 in accordance with the ESMO standard operating procedures for...


Effect of Lisocabtagene Maraleucel on HRQoL and Symptom Severity in Relapsed/Refractory Large B-Cell Lymphoma

HRQoL and symptom improvements across prespecified EORTC QLQ-C30 scales were clinically meaningful in a notable proportion of patients.

Blood Advances
Lenalidomide Triggers T-cell Effector Functions in vivo in Patients With Follicular Lymphoma

Lenalidomide induces early T-cell activation and reprogramming, and restores long-term immune synapse formation in vivo in FL patients.

Blood Advances
Lack of Activation-Induced Cytidine Deaminase Expression in in situ Follicular Neoplasia

The immunoglobulin heavy chain genes undergo class switch recombination and somatic hypermutation to produce a diverse repertoire of high affinity antibodies.

EU Panel Endorses Duvelisib for CLL and Follicular Lymphoma

European Union approval has been recommended for duvelisib for patients with relapsed/refractory CLL or refractory FL who have received at least two prior lines of therapy.

Impact of Transformation on the Survival of Patients Diagnosed With Follicular Lymphoma That Progressed Within 24 Months

This study investigates the occurrence of transformation and its association with POD24 in FL patients receiving RCVP, RCHOP, and BR.

Journal of Cancer
Targeted Treatment of Follicular Lymphoma

Recent advances in understanding of the unique genetic and immune biology of FL have led to increasingly potent and precise novel targeted agents, suggesting that a CT-future...

Journal of Personalized Medicine
3D Model Characterization by 2D and 3D Imaging in t(14;18)-Positive B-NHL: Perspectives for In Vitro Drug Screens in Follicular Lymphoma

Study investigators report a realistic 3D model of t (14;18)-positive B-NHL cell culture, which monitored by state-of-the-art 2D and 3D imaging, allows more robust drug testing.

Inhibitory Effects of Periplocin on Lymphoma Cells: A Network Pharmacology Approach and Experimental Validation

The effects of periplocin on lymphoma and the underlying mechanisms of action remain unclear.

Drug Design, Development and Therapy
The Imbalance of Circulating Follicular T Helper Cell Subsets in Primary Sjögren’s Syndrome Associates With Serological Alterations and Abnormal B-Cell Distribution

This study investigates whether a change in the balance of circulating TFH subsets and follicular regulatory T cells could affect the distribution of B cells in pSS. 

Frontiers in Immunology
Karonudib Has Potent Anti-Tumor Effects in Preclinical Models of B-Cell Lymphoma

Study investigators test the efficacy of karonudib in vitro and in preclinical B-cell lymphoma models. 

Scientific Reports
Genomic Landscape of Cutaneous Follicular Lymphomas Reveals 2 Subgroups With Clinically Predictive Molecular Features

Study investigators propose 3 criteria based on molecular features to predict cases of cutaneous FL with concurrent or future systemic involvement.

Blood Advances
Radiotherapy for Early and Advanced Stages Follicular Lymphoma

This study evaluates the results of radiotherapy for follicular lymphoma under different management scenarios.

Heat Shock Proteins in Lymphoma Immunotherapy

Immunotherapy harnessing the host immune system for tumor destruction revolutionized oncology research and advanced treatment strategies for lymphoma patients.

Frontiers in Immunology
Outcomes of Older Patients With Follicular Lymphoma

Older patients with FL have similar early disease outcomes to younger patients. Age alone should not disqualify older FL patients from standard treatments or RCTs.

Blood Advances
Copanlisib for the Treatment of Malignant Lymphoma: Clinical Experience and Future Perspectives

Ongoing studies of copanlisib in combination with rituximab and standard-of-care chemotherapy in patients with relapsed indolent lymphoma have the potential to support the use of copanlisib...

FDA Grants Accelerated Approval to Axicabtagene Ciloleucel for Relapsed or Refractory Follicular Lymphoma

On March 5, the FDA granted accelerated approval to axicabtagene ciloleucel for adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.

The ASCO Post
Complete Remission of Follicular Lymphoma After SARS-CoV-2 Infection: From the “Flare Phenomenon” to the “Abscopal Effect”

This article describes a 61-year-old patient affected from FL, where end-of-treatment [18F]FDG-PET/CT (panel B) revealed bilateral pneumonia suggestive for COVID-19.

Human Follicular Helper T Lymphocytes Critical Players in Antibody Responses

This review describes aspects of immunobiology and quantification of follicular helper T lymphocytes and circulating follicular helper T lymphocytes...

Unusual Presentation of Recurrent Follicular Lymphoma as Diffuse Granular Shadow

Although the frequency of recurrent FL presenting with diffuse granular shadow is uncommon, recurrent malignant lymphoma should be considered as a differential diagnosis in case...

Overexpression of Aberrant Wnt5a and its Effect on Acquisition of Malignant Phenotypes in Adult T-Cell Leukemia/Lymphoma Cells

This study shows a dramatic increase of WNT5A gene expression in acute-type ATL cells compared with those of indolent-type ATL cells.

Scientific Reports
Establishing a First-Line Treatment Regimen for Follicular Lymphoma

Ansell and Khurana consider bendamustine and rituximab (BR) as their preferred regimen as first-line therapy for a symptomatic patient with follicular lymphoma.

UHRF1 Downregulation Promotes T Follicular Helper Cell Differentiation by Increasing BCL6 Expression in SLE

This study assesses whether UHRF1 can regulate BCL6 expression and influence the differentiation and proliferation of T follicular helper cells.

Significance of Abnormal 53BP1 Expression as a Novel Molecular Pathologic Parameter of Follicular-Shaped B-cell Lymphoid Lesions in Human Digestive Tract

In this study, investigators evaluate the potential of IF-based analysis of 53BP1 expression in differentiating malignant lymphomas from benign lymphoid lesions.

Scientific Reports
Potential Application of T-Follicular Regulatory Cell Therapy in Transplantation

This study discusses the current knowledge of T follicular regulatory cells and the role they play focusing on human diseases and transplantation.

Frontiers in Immunology
Efficacy and Safety Results from CheckMate 140, A Phase 2 Study of Nivolumab For Relapsed/Refractory Follicular Lymphoma

Nivolumab showed promising activity in R/R FL in a phase 1 study.

Copanlisib in the Treatment of Relapsed Follicular Lymphoma: Utility and Experience From the Clinic

The development of PI3K inhibitors has broadened treatment options for R/R FL and currently three PI3K inhibitors have been approved in the third-line setting for FL.

FDA Grants Accelerated Approval to Umbralisib for the Treatment of Marginal Zone Lymphoma and Follicular Lymphoma

On February 5, the US FDA granted accelerated approval to umbralisib, a kinase inhibitor including PI3K-delta and CK1-epsilon.

The ASCO Post
Follicular B-Cell Lymphoma and Particulate Matter Associated with Environmental Exposure to Wood Dust

This case reports highlights a 58-year-old man with follicular B-cell lymphoma.

American Journal of Case Reports
PD-1 Expression in Pre-Treatment Follicular Lymphoma Predicts the Risk of Subsequent High-Grade Transformation

This study investigates the potential of the immune inhibitory programmed death 1 receptor as a biomarker predictive of histological transformation.

Genetic Complexity Impacts the Clinical Outcome of Follicular Lymphoma Patients

The aim of the study is to analyze in detail the genetic landscape and genetic complexity by next-generation sequencing, defined by the number of mutated genes, in a FL series...

Immune-Checkpoint Inhibitors in B-Cell Lymphoma

This review discusses the current advances of immune-checkpoint blockade therapies in B-cell lymphoma and build a projection of how the field may evolve in the near future.

Initial Therapy for Asymptomatic Follicular Lymphoma: Start With Watch and Wait or Rituximab

For patients with indolent follicular lymphoma, generally take a conservative approach to treatment unless the patient is symptomatic.

The ASCO Post
Engineering a Reporter Cell Line to Mimic the High Oligomannose Presenting Surface Immunoglobulin of Follicular Lymphoma B Cells

From deep sequencing of the variable heavy and light chain sequences of follicular lymphoma involved tissue sections, this study identified the consensus variable sequences possessing...

Scientific Reports
Clinical impact of bendamustine exposure on lymphopenia risk after bendamustine and rituximab combination therapy for follicular lymphoma

Bendamustine produces long-lasting objective responses in patients with indolent non-Hodgkin lymphoma, including follicular lymphoma.

Annals of Hematology
C(h)AR-ting a new course in incurable lymphomas: CAR T cells for mantle cell and follicular lymphomas

CD19 CAR T cells have since been tested in largely incurable lymphomas, including mantle cell lymphoma, follicular lymphoma, and marginal zone lymphoma, with promising...

Blood Advances
How Do I Sequence Therapy for Follicular Lymphoma?

In the past decade, many new agents have been introduced for the management of follicular lymphoma, and therapeutic strategies have evolved over time.

Identification of Recurrent Mutations in the microRNA-Binding Sites of B-Cell Lymphoma-Associated Genes in Follicular Lymphoma

Using whole-genome sequencing data from FL tumors, this study discovered 544 mutations located in bioinformatically predicted microRNA-binding sites.

International Journal of Molecular Sciences
Follicular lymphoma t(14;18)-negative is genetically a heterogeneous disease

Fifty-five cases of t(14;18)− follicular lymphoma were genetically characterized by targeted sequencing and copy number arrays.

Blood Advances
MiR-7e-5p downregulation promotes transformation of low-grade follicular lymphoma to aggressive lymphoma by modulating an immunosuppressive stroma through the upregulation of FasL in M1 macrophages

In FL, histologic transformation to high-grade FL and DLBCL is a critical adverse step in disease progression. Activation of the oncogene c-MYC and tumor microenvironment...

Predicting Survival in Veterans with Follicular Lymphoma Using Structured Electronic Health Record Information and Machine Learning

The most accurate prognostic approach for follicular lymphoma, progression of disease at 24 months, requires two years’ observation after initiating first-line therapy to predict outcomes.

International Journal of Environmental Research and Public Health
Multiple Chromosomal Translocations Including Novel CIITA-CREBBP Fusion and Mutations in a Follicular Lymphoma

This case reports a novel fusion gene involving CIITA and CREBBP in a patient with a low-grade follicular lymphoma but with high Ki-67 proliferation index.

Frontiers in Oncology
Human Lymphoid Stromal Cells Contribute to Polarization of Follicular T Cells Into IL-4 Secreting Cells

Previous studies revealed that CXCR5hiPD1hi GC-Tfh are abundant within FL lymph nodes and support directly and indirectly FL B cell survival.

Frontiers in Immunology
Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trial

The Swiss Group for Clinical Cancer Research conducted the SAKK 35/03 randomized trial to investigate different rituximab monotherapy schedules in patients with follicular lymphoma.

Blood Advances
Integrative Analysis of Cell Crosstalk within Follicular Lymphoma Cell Niche: Towards a Definition of the FL Supportive Synapse

Follicular lymphoma, the most frequent indolent non-Hodgkin’s B cell lymphoma, arises from a germinal center B cell proliferation supported by...

Efficacy and Safety of ABP 798: Results from the JASMINE Trial in Patients with Follicular Lymphoma in Comparison with Rituximab Reference Product

ABP 798 is being developed as a biosimilar to rituximab reference product, a CD20-directed cytolytic antibody that is approved in the US and EU for the treatment of NHL.

Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma

Zanubrutinib plus obinutuzumab was safely administered to patients with CLL/SLL and FL, and deep responses were observed.

Blood Advances

Rectal follicular lymphoma is difficult to diagnose due to limited available data, low clinical suspicion and non-specific symptoms.

Primary Gastric Follicular Lymphoma Presenting as a Submucosal Tumor

A 59-year-old man was referred for the detailed examination of a gastric submucosal tumor that had gradually enlarged from a previous examination 4 years ago.

Single-nucleotide variants in TGFB1, TGFBR2, IL17A, and IL17F immune response genes contribute to follicular lymphoma susceptibility and aggressiveness

This present study aimed to test whether 16 SNVs in eight immune-response genes affected FL susceptibility.

Immune Monitoring of Patients With Primary Immune Regulation Disorders Unravels Higher Frequencies of Follicular T Cells With Different Profiles That Associate With Alterations in B Cell Subsets

To improve the understanding of these conditions, this work analyzed the T and B cell compartments of 15 PID patients with dysregulation, including...

Frontiers in Immunology
Primary cutaneous follicle center lymphoma of the breast: Management of an exceedingly rare malignancy

Primary cutaneous follicle center lymphoma is defined as a low-grade B-cell non- Hodgkins lymphoma, which primarily occurs and remains confined to the skin, without evidence of...


source list reference